Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Drug discovery

Chemical diversity targets malaria

Nature volume 538, pages 323–325 (2016)Cite this article

Subjects

A molecule selected from a library of compounds that have structures similar to natural products targets several stages of the malarial parasite's life cycle, offering single-dose treatment of the disease in mouse models. See Article p.344

Eliminating malaria would save more than 400,000 lives annually, mainly those of young children in sub-Saharan Africa, and prevent the approximately 200 million cases of the disease that arise each year1. Achieving this will require medicines that can eliminate all three stages of Plasmodium parasite infection in humans. On page 344, Kato et al.2 report compounds, known as bicyclic azetidines, that display this multistage activity.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Figure 1: A compound that targets all parasite stages of malarial infection.

Notes

  1. See all news & views

References

  1. WHO. World Malaria Report 2015 www.who.int/malaria/publications/world-malaria-report-2015/report/en (2015).

  2. Kato, N. et al. Nature 538, 344–349 (2016).

    Article  CAS  ADS  Google Scholar 

  3. Ashley, E. A. et al. N. Engl. J. Med. 371, 411–423 (2014).

    Article  Google Scholar 

  4. Leang, R. et al. Antimicrob. Ag. Chemother. 59, 4719–4726 (2015).

    Article  CAS  Google Scholar 

  5. Lowe, J. T. et al. J. Org. Chem. 77, 7187–7211 (2012).

    Article  CAS  Google Scholar 

  6. Wells, T. N. C., Hooft van Huijsduijnen, R. & Van Voorhis, W. C. Nature Rev. Drug Discov. 14, 424–442 (2015).

    Article  CAS  Google Scholar 

  7. Pham, J. S. et al. Int. J. Parasitol. Drugs Drug Res. 4, 1–13 (2014).

    Article  Google Scholar 

  8. Corey, V. C. et al. Nature Commun. 7, 11901 (2016).

    Article  CAS  ADS  Google Scholar 

  9. Baragaña, B. et al. Nature 522, 315–320 (2015).

    Article  ADS  Google Scholar 

  10. Phillips, M. A. et al. Sci. Transl. Med. 7, 296ra111 (2015).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. David A. Fidock is in the Departments of Microbiology and Immunology and of Medicine, Division of Infectious Diseases, Columbia University Medical Center, New York, New York 10032, USA.,

    David A. Fidock

Authors
  1. David A. Fidock
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David A. Fidock.

Related links

Related links

Related links in Nature Research

Malaria: Fifteen years of interventions

Microbiology: Malaria runs rings round artemisinin

Rights and permissions

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fidock, D. Chemical diversity targets malaria. Nature 538, 323–325 (2016). https://doi.org/10.1038/nature19481

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nature19481

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research